← Back to screener

Esperion Therapeutics, Inc. ESPR

Rank #1989 · Nasdaq · $0.8B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
37.0
P/E
-3.9
P/B
-2.53
ROE
64.6%
Op. Margin
-133.7%
Debt Ratio
-226%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -3.9x, P/B -2.53x. Ranks in the top 96% of the universe.

Profitability ★★★☆☆
Average

ROE 64.6%. Ranks in the top 48% of the universe.

Safety ★★★★★
Excellent

Debt ratio -226%. Ranks in the top 5% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★★
Excellent

Revenue growth of 54.1% year over year. Ranks in the top 7% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2013–$-0.0B$-0.0B$-0.0B–-128
2014–$-0.0B$-0.0B$-0.0B–-14
2015–$-0.0B$-0.0B$-0.0B–-24
2016–$-0.0B$-0.0B$0.1B–11
2017–$-0.1B$-0.0B$0.1B–12
2018–$-0.1B$-0.1B$0.3B–12
2019$0.1B$-0.2B$-0.2B$0.2B-113.928
2020$0.0B$-0.2B$-0.2B$0.2B–79
2021$0.1B$-0.1B$-0.1B$0.1B-62.8568
2022$0.1B$-0.2B$-0.3B$-0.1B-289.0-602
2023$0.1B$-0.2B$-0.2B$-0.2B-237.8-290
2024$0.1B$-0.2B$-0.2B$-0.2B-237.8-336
2025$0.1B$-0.2B$-0.2B$-0.3B-133.7-226

← See the full screener